Novum Law recognised in prestigious Chambers & Partners Guide 2024
The team at Novum Law are delighted to be once again recognised as one of the best personal injury law firms in the South West by the leading, independent legal...
It has been reported that Amatuximab could be used to make chemotherapy more effective for those people who are suffering from malignant mesothelioma.
Researchers are currently studying Amatuximab as part of an International trial, and the recently published results reportedly show some encouraging news for mesothelioma patients.
Amatuximab is an antibody that has been developed to help in the treatment of people whose cancer cells over express the protein mesothelin. The Amatuximab binds to the mesothelin and stops the cells from dividing. A trial under the name of ARTEMIS has used the compound as a treatment of pleural mesothelioma, together with the standard chemotherapy treatments of Pemetrexed and Cisplatin.
The Amatuximab is still ongoing, but the newest study reportedly examines the way the drug moves through the bodies of patients with mesothelioma, and its effect on their survival.
The newly published report reportedly shows that in patients whose bodies absorb the highest amount of Amatuximab, the drug had a significant effect on overall survival and on progression free survival. A trial of Amatuximab in mesothelioma patients with mesothelioma is still recruiting patients at a number of centres across the World.
Andrew Stinchcombe at Novum Law comments “Mesothelioma is a condition that can take many decades to develop. It is only now that we are reaching the peak of cases that are emerging in the United Kingdom. We therefore welcome further research into potential treatments and possible cures, and we hope that more funding will be made available to treat a disease which at present unfortunately remains incurable”.
To read the full article, click here.
